Sana Biotechnology (NASDAQ:SANA – Get Free Report) and PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider & Institutional Ownership
88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 34.2% of PharmaCyte Biotech shares are held by institutional investors. 34.9% of Sana Biotechnology shares are held by insiders. Comparatively, 7.3% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Sana Biotechnology and PharmaCyte Biotech’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Sana Biotechnology | N/A | -88.36% | -47.89% |
PharmaCyte Biotech | N/A | -9.69% | -5.86% |
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Sana Biotechnology | N/A | N/A | -$283.26 million | ($1.47) | -5.50 |
PharmaCyte Biotech | N/A | N/A | -$4.32 million | ($1.20) | -1.78 |
Sana Biotechnology is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Sana Biotechnology and PharmaCyte Biotech, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Sana Biotechnology | 0 | 1 | 3 | 0 | 2.75 |
PharmaCyte Biotech | 0 | 0 | 0 | 0 | N/A |
Sana Biotechnology currently has a consensus target price of $11.67, indicating a potential upside of 44.21%. Given Sana Biotechnology’s higher possible upside, equities analysts clearly believe Sana Biotechnology is more favorable than PharmaCyte Biotech.
Volatility and Risk
Sana Biotechnology has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500.
About Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.